• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cassava Sciences to Hold Corporate Update on November 25th

    11/24/24 8:01:09 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SAVA alert in real time by email

    AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time.

      
    Event Details:
      
    Date: Monday, November 25th
    Time: 8:00 a.m. Eastern Time
    Webcast: https://lifescievents.com/event/cassava/
      

    A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences website for 90 days following the webcast.

    About Cassava Sciences, Inc.

    Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer's disease.

    Simufilam is an investigational oral, small molecule drug candidate currently being evaluated in two Phase 3 clinical trials for the potential treatment of Alzheimer's disease. Simufilam is a proprietary, investigational oral small molecule that targets the filamin A protein. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.

    For more information, please visit: https://www.CassavaSciences.com

    For More Information Contact:

    Investors

    Sandya von der Weid

    [email protected]

    Media

    [email protected]

    Company

    Eric Schoen, Chief Financial Officer

    (512) 501-2450

    [email protected] 

    [email protected]



    Primary Logo

    Get the next $SAVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • When is the conference call and webcast scheduled?

      Cassava Sciences, Inc. will hold a conference call and webcast on November 25 at 8:00 a.m. Eastern Time.

    • What date and time will the conference call take place?

      The conference call is scheduled for Monday, November 25, 2024 at 8:00 a.m. Eastern Time.

    • Will there be a replay available for the conference call?

      Yes, a replay of the audio webcast will be available on the Cassava Sciences website for 90 days after the event.

    • What is Simufilam and what is its current status?

      Simufilam is an investigational oral drug candidate being evaluated in Phase 3 clinical trials for Alzheimer's disease.

    • What is the main focus of Cassava Sciences?

      Cassava Sciences is focused on developing treatments for neurodegenerative diseases, particularly Alzheimer's disease.

    Recent Analyst Ratings for
    $SAVA

    DatePrice TargetRatingAnalyst
    11/26/2024Buy → Neutral
    H.C. Wainwright
    10/8/2024$116.00Neutral → Buy
    H.C. Wainwright
    7/1/2024Buy → Neutral
    H.C. Wainwright
    11/16/2022$44.00Buy → Neutral
    B. Riley Securities
    1/24/2022$108.00 → $72.00Buy
    B. Riley Securities
    7/20/2021$97.00 → $124.00Buy
    HC Wainwright & Co.
    7/15/2021$100.00Overweight → Neutral
    Cantor Fitzgerald
    7/7/2021$80.00 → $190.00Buy
    Maxim Group
    More analyst ratings

    $SAVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cassava Reports Q1 2025 Financials Results, Provides Business Update

      License agreement and recent leadership appointments position Cassava to advance development of simufilam in TSC-related epilepsy $117.3 Million in Cash and Cash Equivalents at March 31, 2025 AUSTIN, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. "Cassava has made significant progress this year in leveraging our science to expand our portfolio. Our license with Yale University for inte

      5/8/25 8:00:00 AM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

      As SVP, Neuroscience, Dr. Bordey will lead Cassava's ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that Angélique Bordey, PhD, has joined the Company as Senior Vice President (SVP), Neuroscience, while continuing her tenured academic position at Yale School of Medicine on a part time basis. Dr. Bor

      5/1/25 7:30:00 AM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

      AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system (CNS) disorders such as tuberous sclerosis complex (TSC)-related epilepsy, today announced the retirement of James W. Kupiec, MD, Chief Medical Officer, effective May 9, 2025. The Company also appointed Jack Moore, PhD, as Senior Vice President, Clinical Development, reporting to Rick Barry, Chief Executive Officer. "The entire Cassava team is grateful for Jim's service as our Chief Medical Officer. He is retiring after a notable care

      4/21/25 4:30:00 PM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Schoen Eric

      4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

      4/21/25 4:51:38 PM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President & CEO Barry Richard

      4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

      4/21/25 4:49:55 PM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Business Officer Nassif Freda

      4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

      4/21/25 4:45:52 PM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAVA
    Financials

    Live finance-specific insights

    See more
    • Cassava Sciences to Hold Corporate Update on November 25th

      AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time.    Event Details:    Date: Monday, November 25th Time: 8:00 a.m. Eastern Time Webcast: https://lifescievents.com/event/cassava/    A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences website for 90 days following the webcast. About Cassava Sciences, Inc. Cassava Sciences is a clinical-stage biotechnolog

      11/24/24 8:01:09 PM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

      AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.   Event details:  Date:Thursday, November 7thTime:8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOrAudio Webcast:https://edge.media-server.com/mmc/p/tzb9j3sy   A replay of the audio webcast will also be available on the "Company Presentations" page of the Cassava Sciences website for 90 days following the webcast. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnolo

      10/31/24 8:30:00 AM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET

      AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, August 8th at 8:30 a.m. Eastern Time. Event details follow:Date:Thursday, August 8thTime: 8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOr Audio Webcast:https://edge.media-server.com/mmc/p/zjvmjjcr   A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences' website for 90 days following the webcast. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnolo

      8/1/24 8:30:00 AM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAVA
    SEC Filings

    See more

    $SAVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SAVA
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form 10-Q filed by Cassava Sciences Inc.

      10-Q - CASSAVA SCIENCES INC (0001069530) (Filer)

      5/8/25 4:01:39 PM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CASSAVA SCIENCES INC (0001069530) (Filer)

      5/8/25 8:15:10 AM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Sciences Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CASSAVA SCIENCES INC (0001069530) (Filer)

      4/21/25 4:37:46 PM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Sciences downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Cassava Sciences from Buy to Neutral

      11/26/24 7:44:43 AM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Sciences upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Cassava Sciences from Neutral to Buy and set a new price target of $116.00

      10/8/24 8:06:57 AM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Sciences downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Cassava Sciences from Buy to Neutral

      7/1/24 7:48:24 AM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

      As SVP, Neuroscience, Dr. Bordey will lead Cassava's ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that Angélique Bordey, PhD, has joined the Company as Senior Vice President (SVP), Neuroscience, while continuing her tenured academic position at Yale School of Medicine on a part time basis. Dr. Bor

      5/1/25 7:30:00 AM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

      AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system (CNS) disorders such as tuberous sclerosis complex (TSC)-related epilepsy, today announced the retirement of James W. Kupiec, MD, Chief Medical Officer, effective May 9, 2025. The Company also appointed Jack Moore, PhD, as Senior Vice President, Clinical Development, reporting to Rick Barry, Chief Executive Officer. "The entire Cassava team is grateful for Jim's service as our Chief Medical Officer. He is retiring after a notable care

      4/21/25 4:30:00 PM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

      Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs Appointment initiates Cassava's commercial readiness strategy as the Company prepares for first Phase 3 topline data readout before year end 2024 AUSTIN, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced the appointment of Freda Nassif as Chief Commercial Officer, effective today. As a member of the Company's executive leadership team, Ms. Nassif will report to Richard "Rick" Barry, President and Chief Executive of Cas

      11/18/24 8:30:00 AM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cassava Sciences Inc.

      SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

      11/4/24 4:09:49 PM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cassava Sciences Inc. (Amendment)

      SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

      2/13/24 5:01:04 PM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cassava Sciences Inc. (Amendment)

      SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

      2/1/24 4:00:47 PM ET
      $SAVA
      Biotechnology: Pharmaceutical Preparations
      Health Care